FOLH1 and neoplasm: Patients’ selection for PRLT is based on PSMA uptake intensity compared to normal tissues uptake assessed either on a visual analysis as used in the VISION trial [30] or a semi-quantitative analysis calculating the maximal Standard Uptake Value (SUVmax) in a tumor region of interest, like for the TheraP trail [29].